Actively Recruiting

Age: 18Years +
All Genders
ID06781242

Genotype-Phenotype Relationship Between Adult Cryptogenic Cholestasis and Mutations in Genes Responsible for Progressive Familial Intrahepatic Cholestasis

Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-17

300

Participants Needed

2

Research Sites

34 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the relationship between gene mutations and adult cryptogenic cholestasis, a type of cholestatic liver disease. This study focuses on mutations in genes responsible for progressive familial intrahepatic cholestasis (PFIC). The goal is to better understand how these gene mutations relate to different clinical presentations, identify risk factors, and eventually support personalized treatments for affected patients. This is a multicenter, retrospective observational study collecting data on patients diagnosed with cholestatic liver diseases, including PFIC, cryptogenic cholestatic liver diseases (CCLDs), and hepatobiliary cancer (HBC). Diagnoses are confirmed through imaging studies, and cases with other known liver disease causes are excluded. The study gathers existing patient data from May 2013 until the study start date. Participants will have their gene mutations classified and clinical and histological outcomes assessed over a 12-month period. Researchers will evaluate mutation types in PFIC genes and observe related clinical features and liver tissue patterns. Data collection involves reviewing patient records and diagnostic imaging. Safety monitoring is not applicable as this is an observational study with no interventions, and participant involvement focuses on data review.

CONDITIONS

Brief Title

Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Diagnosis of progressive familial intrahepatic cholestasis, cryptogenic cholestatic liver diseases, or hepatobiliary cancer
  • Ability to provide informed consent
Not Eligible

You will not qualify if you...

  • Presence of another documented chronic liver disease that explains the clinical phenotype

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surveillance

Duration - Up to 12 months

Participants with cholestatic liver diseases are observed to gather information on genetic mutations and clinical presentations.

Data collection occurs retrospectively from May 2013 until study start; no additional visits are required.

Trial Site Locations

Total: 2 locations

1

IRCCS - Azienda Ospedaliero-Universitaria di Bologna

Bologna, Bologna, Italy, 40138

Actively Recruiting

2

Ospedale Civile Sant'Agostino Estense Baggiovara

Modena, Modena, Italy, 41126

Actively Recruiting

Loading map...

Research Team

G

Giovanni Vitale, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Registry to Document Treatment Effectiveness, Safety, Includ...

Progressive Familial Intrahepatic Cholestasis

Actively Recruiting

1 location

Registry to Document Treatment Effectiveness, Safety, Includ...

Progressive Familial Intrahepatic Cholestasis

Actively Recruiting

3 locations

cfDNA Assay Multicenter Prospective Observational Validation...

Brain Cancer

Actively Recruiting

17 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here